Lisata Therapeutics (NASDAQ:LSTA) Stock Price Down 3.9% – Time to Sell?

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s stock price fell 3.9% during trading on Friday . The company traded as low as $1.92 and last traded at $1.97. 29,264 shares changed hands during trading, an increase of 35% from the average session volume of 21,665 shares. The stock had previously closed at $2.05.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LSTA. Zacks Research lowered shares of Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $23.50.

Lisata Therapeutics Price Performance

The stock’s 50-day moving average is $2.17 and its two-hundred day moving average is $2.39. The company has a market cap of $17.38 million, a P/E ratio of -0.92 and a beta of 1.09.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Thursday, November 6th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.05. On average, analysts predict that Lisata Therapeutics, Inc. will post -2.66 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Ground Swell Capital LLC purchased a new stake in shares of Lisata Therapeutics during the 3rd quarter valued at about $62,000. CIBC Bancorp USA Inc. purchased a new position in shares of Lisata Therapeutics in the third quarter worth approximately $37,000. Finally, Cerity Partners LLC purchased a new position in shares of Lisata Therapeutics in the second quarter worth approximately $32,000. 8.94% of the stock is owned by hedge funds and other institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.